Cardio Diagnostics shares jump 10.22% premarket after presenting data on PrecisionCHD's detection of INOCA and MINOCA.

Cardio Diagnostics Holdings surged 10.22% in premarket trading following the announcement that its PrecisionCHD test demonstrated a strong ability to detect INOCA and MINOCA, two underdiagnosed heart conditions, with an area under the curve (AUC) of 0.90 in a study presented at the AHA Scientific Sessions. The data, derived from 267 patients and validated by the University of Iowa, highlights the test’s potential to address a critical gap in cardiovascular diagnostics by offering a non-invasive, accessible alternative to invasive procedures. The findings reinforce the company’s position in precision cardiovascular medicine and underscore the test’s capacity for personalized, actionable insights, particularly for women and patients in rural or underserved areas. The event aligns with broader industry demand for innovative diagnostic tools and positions Cardio Diagnostics to expand its market relevance in a high-stakes healthcare sector.